COMMUNIQUÉS West-GlobeNewswire

Augmedix Delivers 27% Revenue Growth for Second Quarter of 2024
12/08/2024
SAN FRANCISCO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Augmedix (Nasdaq: AUGX), a leader in ambient AI medical documentation and data solutions, today reported financial results for the three months ended June 30, 2024. “We [...]
MDxHealth to Present Second Quarter and First Half 2024 Financial Results and Corporate Update on August 21
12/08/2024
MDxHealth to Present Second Quarter and First Half 2024 Financial Results and Corporate Update on August 21 Company to Host Conference Call with Live Q&A, August 21, 2024, at 4:30pm ET / 22:30 CET IRVINE, CA, and [...]
Eric Samples Joins PetVivo Holdings, Inc. as a Field Veterinary Business Development Manager
12/08/2024
MINNEAPOLIS, MN, US, Aug. 12, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV & PETVW) (the "Company") an emerging biomedical device company focused on the commercialization of innovative medical [...]
NeuroOne® to Report Third Quarter Fiscal Year 2024 Financial Results and Provide Corporate Update on August 14
12/08/2024
EDEN PRAIRIE, Minn., Aug. 12, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and [...]
Milestone Scientific Schedules Second Quarter 2024 Financial Results and Business Update Conference Call
12/08/2024
ROSELAND, N.J., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments, that provide painless and precise injections, today announced that [...]
Zealand Pharma conference call on August 15 at 2pm CET (8am ET) to present first half 2024 financial results
12/08/2024
Press Release – No. 8 / 2024 Zealand Pharma conference call on August 15 at 2pm CET (8am ET) to present first half 2024 financial results Copenhagen, Denmark, August 12, 2024 – Zealand Pharma A/S (Nasdaq Copenhagen: [...]
scPharmaceuticals Announces Pricing of $50.0 Million Public Offering
12/08/2024
BURLINGTON, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of [...]
Junshi Biosciences Announces Acceptance of Supplemental New Drug Application for Toripalimab as First-Line Treatment of Unresectable/Metastatic Melanoma
12/08/2024
SHANGHAI, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, [...]
NEXGEL to Report Second Quarter 2024 Financial Results on August 14th
12/08/2024
Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa., Aug. 12, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over- [...]
60 Degrees Pharma Provides University of Kentucky with Right of Reference to ARAKODA® NDA in Support of SJ733 Phase IIb Study
12/08/2024
University of Kentucky will commence a Phase IIb clinical study of drug development candidate SJ733 for treatment of vivax malaria. SJ733 will be combined with a single dose of tafenoquine in the study. The right of [...]
Outlook Therapeutics® to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
12/08/2024
ISELIN, N.J., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg; bevacizumab [...]
Health AI Company Akido Establishes Ethics Council on Artificial Intelligence in Healthcare with Caltech’s Merkin Institute and the Keck School of Medicine of USC Department of Surgery
12/08/2024
Akido’s Breakthrough AI Unlocks a Reimagined Care Experience with a Focus on Bringing Exceptional Healthcare to All The Council will Establish Ethical Guidelines for the AI Industry and the Technology’s Integration into [...]
MAPS Statement on FDA Complete Response Letter for MDMA-Assisted Therapy for PTSD New Drug Application
10/08/2024
MAPS remains confident in its goal of making access to MDMA-assisted therapy for PTSD safe and legal SAN JOSE, Calif., Aug. 09, 2024 (GLOBE NEWSWIRE) -- The Multidisciplinary Association for Psychedelic Studies ( MAPS [...]
PharmAla Comments on USFDA Decision regarding MDMA-Assisted Therapy and Announces Patent Granting for ALA-002
10/08/2024
TORONTO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“ PharmAla ” or the “ Company ”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of [...]
Skye Bioscience Reports Second Quarter 2024 Financial Results and Recent Highlights
09/08/2024
Advancement of clinical and regulatory steps enable the expected initiation of Phase 2 obesity clinical trial for nimacimab peripheral CB1 inhibitor in Q3 2024 SAN DIEGO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Skye [...]
ZyVersa Therapeutics Reports Second Quarter, 2024 Financial Results and Provides Business Update
09/08/2024
KEY HIGHLIGHTS Phase 2a clinical trial for Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease on track to begin H2-2024. Obesity with related metabolic complications selected as lead [...]
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09/08/2024
CAMBRIDGE, Mass., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with [...]
Belite Bio Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
09/08/2024
Tinlarebant, a novel oral therapy, is intended to slow disease progression in patients affected with Stargardt Disease (STGD1) and Geographic Atrophy (GA) in advanced Dry Age-related Macular Degeneration (Dry AMD) Phase [...]
Edesa Biotech Reports Fiscal 3rd Quarter 2024 Results
09/08/2024
TORONTO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported [...]

Pages